| INSTITUT PASTEUR Patent applications |
| Patent application number | Title | Published |
|---|
| 20120100116 | NEURON GENERATION, REGENERATION AND PROTECTION - The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress. | 04-26-2012 |
| 20120094312 | BOOSTING HUMAN DENDRITIC CELL DEVELOPMENT, HOMEOSTASIS AND FUNCTION IN XENOGRAFTED IMMUNODEFICIENT MICE - The present invention relates to a transgenic animal mode system based on the development of transgenic mice bearing components of the human immune system. Specifically, the Invention relates to a Flk2 deficient Rag “γc” transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further presides methods for increasing the numbers of functionally competent human dendritic cells is and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential Immune adjuvants and for developing novel therapeutics. | 04-19-2012 |
| 20120088718 | HCV-DERIVED POLYPEPTIDES AND USES THEREOF - The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections. | 04-12-2012 |
| 20120088676 | MOLECULAR TYPING AND SUBTYPING OF SALMONELLA BY IDENTIFICATION OF THE VARIABLE NUCLEOTIDE SEQUENCES OF THE CRISPR LOCI - The present invention relates to a method for detecting and identifying bacteria of the | 04-12-2012 |
| 20120073003 | APOBEC3 MEDIATED DNA EDITING - The present invention relates to methods and compositions for preventing the occurance or progression of a cancer or pre-cancerous condition associated with expression, or over-expression of human cytidine deaminases of the APOBEC3 family. The invention also relates to drug screening assays designed to identify compounds that regulate the activity, or level of expression, of hA3A, hA3C and hA3H. The invention further relates to transgenic mice, as well as cells derived from said mice, that have been genetically engineered to express, or over-express hA3A, hA3C and/or hA3H. Such mice may be utilized to screen for, or identify, compounds that modulate the activity, or expression, of the human cytidine deaminases. The present invention also provides topical compositions such as cosmetic lotion, crème, or sunscreen for use on the skin, which comprise one or more inhibitors of human cytidine deaminase activity. The present invention relates to a double stranded DNA obtained following opening up of its duplex structure, said DNA being edited with cellular protein normally or abnormally expressed in the nucleus of an eukaryotic cell. The mono stranded DNA derived from the said double stranded DNA is a part of the present invention. | 03-22-2012 |
| 20120040848 | MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN - The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient. | 02-16-2012 |
| 20120034604 | USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER - The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use. | 02-09-2012 |
| 20110311581 | REVERSE GENETICS OF NEGATIVE-STRAND RNA VIRUSES IN YEAST - The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA. | 12-22-2011 |
| 20110305667 | USE OF A DEAD-BOX RNA HELICASE FOR INDUCING CYTOKINE PRODUCTION - The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, | 12-15-2011 |
| 20110287406 | Novel HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents - The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG. | 11-24-2011 |
| 20110268757 | USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer | 11-03-2011 |
| 20110244491 | PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES - The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject. | 10-06-2011 |
| 20110229474 | MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE - Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample. | 09-22-2011 |
| 20110223186 | Clostridium toxin, and process for the preparation of immunogenic composition - The present invention relates to the field of bacterial toxic proteins, in particular toxins from | 09-15-2011 |
| 20110182811 | NUCLEOTIDE SEQUENCE ENCODING A MODULATOR OF NF-KB - The present invention relates to nucleotide sequences encoding a modulator of NF-κB, and to the polypeptides encoded by the nucleotide sequences. In particular, the invention relates to nucleotide sequences and the polypeptides encoded thereby, wherein the polypeptides are involved in the response to NF-κB-activating stimuli, including HTLV-1 Tax, LPS, PMA and IL-1. The invention also relates to antibodies to the modulator of NF-κB, methods of detecting modulator of NF-κB using the antibodies, methods of treatment associated with NF-κB activation and to methods of identifying compounds which modulate the activity of the modulator of NF-κB. | 07-28-2011 |
| 20110178021 | OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT - The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder. | 07-21-2011 |
| 20110171244 | RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMAVIRUS EPITOPES INSERTED IN AN ADENYLATE CYCLASE PROTEIN OR FRAGMENT THEREOF THERAPEUTIC USES THEREOF - The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects. | 07-14-2011 |
| 20110159598 | CRYSTAL STRUCTURE OF THE CCZ-LZ DOMAIN OF NEMO - The invention relates to a crystal of the CC2-LZ domain of the NEMO protein, in which the three-dimensional structure has been determined by X-ray diffraction at a resolution of about 3.25 A. The invention also relates to methods for the crystallisation of the CC2-LZ domain. The CC2-LZ crystals and the information derived from the crystalline structures thereof are used for identifying and designing compounds interacting with CC2-LZ. | 06-30-2011 |
| 20110159480 | CELL-BASED SCREENING ASSAY TO IDENTIFY MOLECULES THAT STIMULATE IFN-ALPHA/BETA TARGET GENES - A method using cells transformed with a construct containing a reporter gene operatively-linked to an interferon stimulated response element for identifying an agent, such as a chemical compound, peptide or polypeptide, which exhibits an interferon-like activity on the interferon stimulated response element (ISRE) and modulates genes activated by activation of the ISRE. | 06-30-2011 |
| 20110142862 | TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS - The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2 | 06-16-2011 |
| 20110124571 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 05-26-2011 |
| 20110104138 | USE OF THE INNATE IMMUNITY GENE OASL FOR PREVENTING OR TREATING INFECTION WITH NEGATIVE STRAND RNA VIRUSES - A method to treat a disease, disorder or condition caused by a negative-sense single-strand RNA virus in an individual in need, comprising at least the step of administering to said individual in need, an isolated 2′-5′-oligoadenylate synthetase like protein or an isolated polynucleotide encoding said 2′-5′-oligoadenylate synthetase like protein. | 05-05-2011 |
| 20110091969 | MUTATIONS IN THE NS5B PROTEIN OF THE HCV - An NS5B protein of the hepatitis C virus (HCV), with good replication performance, has a point mutation in at least one of the following positions:
| 04-21-2011 |
| 20110086767 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES - Method for preparing the disaccharide α-D-glucopyranosyl-(1→4)-2-N-acetyl-2-deoxy-α-D-glucopyranoside, comprising the step of using a mutant of a wild type glycoside hydrolase. | 04-14-2011 |
| 20110065089 | NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF - The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine. | 03-17-2011 |
| 20110059855 | Use of adiponectin for the diagnosis and/or treatment of presbycusis - The present invention relates to mutations located within the gene coding for adiponectin, said mutations being associated with presbycusis. The present invention further relates to adiponectin polynucleotides comprising such mutations, to adiponectin polypeptides encoded by such polynucleotides, and to methods of diagnosing and/or treating presbycusis using adiponectin polynucleotides, adiponectin polypeptides and/or ADIPOR2 polypeptides. | 03-10-2011 |
| 20110045475 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 02-24-2011 |
| 20110039262 | METHODS FOR DETECTING VIRULENT PLASMODIUM, FOR EVALUATING PLASMODIUM VIRULENCE, AND FOR SCREENING NEW DRUGS EMPLOYING THE 3'UTR OF PLASMODIUM SUB2 AND THE PLASMODIUM SUB2 SERINE PROTEASE - Methods for regulating the serine protease of | 02-17-2011 |
| 20110034383 | CXCL12 GAMMA A CHEMOKINE AND USES THEREOF - Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans. | 02-10-2011 |
| 20110028387 | METHODS OF SCREENING OF PP1-INTERACTING POLYPEPTIDES OR PROTEINS, PEPTIDES INHIBITING PP1c BINDING TO Bcl-2 PROTEINS, BCL-XL AND BCL-W, AND USES THEREOF - The invention relates to methods for identifying novel PP1-interacting polypeptides and proteins, compounds which are able to inhibit the binding of PP1c to certain factors naturally interacting with it, especially proteins of the Bcl-2 family (such as Bcl-x | 02-03-2011 |
| 20110027318 | NUCLEOTIDE VECTOR, COMPOSITION CONTAINING SUCH VECTOR, AND VACCINE FOR IMMUNIZATION AGAINST HEPATITIS - Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers. | 02-03-2011 |
| 20110021369 | SINGLE CELL BASED REPORTER ASSAY TO MONITOR GENE EXPRESSION PATTERNS WITH HIGH SPATIO-TEMPORAL RESOLUTION - The invention relates to a double-stranded polynucleotide comprising on its positive strand considered from its 5′ end to its 3′ end, (i) a promoter of a gene of interest or several promoters of various genes of interest selected among genes which are endogenous to a determined cell, and, (ii) one or several barcode(s) wherein each barcode contains at least one barcode unit formed of at least one, especially of multiple, recognition binding sites each binding site being composed of a nucleotide sequence, and wherein each of said barcode(s) is under the control of at least one of said promoter(s) for transcription. It further concerns use of said polynucleotide to monitor gene expression patterns in living cells, especially in single cells, with a rapid and high spatio-temporal resolution. | 01-27-2011 |
| 20110020928 | IMMUNOVECTORS WHICH CAN BE USED FOR THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT - A method of transferring a biologically active principle of interest into a cell by coupling an antibody or a fragment of an antibody, which recognizes an epitope contained in a nucleic acid, with the biologically active principle, to form a coupled biologically active principle; and incubating the coupled biologically active principle, which is transferred through the cell membrane and into the cell, with the cell. | 01-27-2011 |
| 20110003282 | DIFFERENTIAL AMPLIFICATION OF MUTANT NUCLEIC ACIDS BY PCR IN A MIXTURE OF NUCLEIC ACIDS - A method for enriching a mutant nucleic acid in a mixture of nucleic acids, wherein the method comprises: (a) providing a nucleic acid mixture comprising a parental nucleic acid and a mutant nucleic acid of the parental nucleic acid; and (b) amplifying the nucleic acids in the nucleic acid mixture by polymerase chain reaction (PCR); wherein the mutant nucleic acid is a G→A mutant of the parental nucleic acid, which pairs with a fully complementary nucleic acid sequence to form an AT-rich nucleic acid variant of the parental nucleic acid; and wherein the AT-rich nucleic acid variant is denatured and selectively amplified by carrying out PCR using a denaturation temperature 1-3° C. lower than the lowest denaturation temperature (T | 01-06-2011 |
| 20100330667 | CHIMERIC GFP-AEQUORIN AS BIOLUMINESCENT CA++ REPORTERS AT THE SINGLE CELL LEVEL - A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET). | 12-30-2010 |
| 20100330560 | Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof - The present invention relates to an immunogenic polypeptide isolated from | 12-30-2010 |
| 20100304408 | USE OF THE ALPHA CHAIN OF BRAIN SPECTRIN AND FRAGMENTS THEREOF, FOR DIAGNOSING CEREBRAL DISEASES - The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed. | 12-02-2010 |
| 20100297632 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 11-25-2010 |
| 20100297168 | LENTIVIRAL GENE TRANSFER VECTORS AND THEIR MEDICINAL APPLICATIONS - The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors are either integrative or non-integrative (NI) vectors, dependently upon the purpose of their use. The invention relates to the use of gene transfer vectors for unique or for multiple in vivo administration into a host in need thereof. The field of application of the present application concerns in particular animal treatment or treatment of human being (e.g. prophylactic or therapeutic or symptomatic or curative treatment), gene therapy or vaccination in vivo. These vectors may be used to elicit an immune response to prevent or to treat a pathogenic state, including virus infections (for example treatment or prevention against Immunodeficiency Virus and especially against AIDS), parasite and bacterial infections or cancers, and preferably to elicit a protective, long-lasting immune response. | 11-25-2010 |
| 20100291133 | RECOMBINANT PROTEIN CONTAINING A C-TERMINAL FRAGMENT OF PLASMODIUM MSP-1 - The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the | 11-18-2010 |
| 20100291095 | IDENTIFICATION OF A CONSERVED REGION OF PLASMODIUM FALCIPARUM MSP3 TARGETED BY BIOLOGICALLY ACTIVE ANTIBODIES - Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of different combinations of the MSP3 a, b, c, d, e and f peptides. Particular non-overlapping or overlapping segments of MSP3 a, b, c, d, e and f peptides may also be used. The various overlapping segments and nonoverlapping segments among the different MSP3 peptides are shown in FIG. | 11-18-2010 |
| 20100278872 | MEDICAMENTS AND METHODS FOR TREATING MESOTHELIOMA - The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual. | 11-04-2010 |
| 20100273723 | PEPTIDES OF IL-2 - The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. | 10-28-2010 |
| 20100272756 | GRAM POSITIVE BACTERIA PREPARATIONS FOR THE TREATMENT OF DISEASES COMPRISING AN IMMUNE DYSREGULATION - This application relates to compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intracellular bacteria for treatment of disorders comprising an immune dysregulation in humans and animals. | 10-28-2010 |
| 20100272707 | ENZYMATIC LARGE-SCALE SYNTHESIS OF MUCIN GLYCONJUGATES, AND IMMUNOGENIC APPLICATIONS THEREOF - The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG). | 10-28-2010 |
| 20100260758 | IN VIVO MODULATION OF NEURONAL TRANSPORT - The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid. | 10-14-2010 |
| 20100255038 | PURIFIED POLYPEPTIDE COMPRISING OR CONSISTING OF A C-TERMINUS MSP1 ANTIGEN FROM PLASMODIUM FALCIPARUM CARRYING A GLYCOSYL-PHOSPHATIDYL-INOSITOL GROUP (GPI) - The present invention relates to a purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from | 10-07-2010 |
| 20100255018 | POLYNUCLEOTIDES AND POLYPEPTIDES INVOLVED IN GESTATIONAL MALARIA, AND BIOLOGICAL APPLICATIONS - The present invention relates to novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including said sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to the use thereof for treating gestational malaria. The invention also relates to diagnostic methods and kits. | 10-07-2010 |
| 20100240040 | METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-KB PATHWAY ACTIVATION - The invention relates to methods for screening for selective modulator of NF-κB pathway activation. The invention concerns methods for primary screening molecules that potentially modulate (activate or inhibit) the NF-κB pathway activation by identifying and selecting molecules modulate the interaction of NEMO with other proteins. The invention also concerns methods for secondary screening for modulator (activator or inhibitor) of the NF-κB pathway activation. | 09-23-2010 |
| 20100239584 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X - The present invention relates to compounds derived from sugars which reproduce the epitopes of | 09-23-2010 |
| 20100196943 | IDENTIFICATION AND CHARACTERIZATION OF RACEMASES, DEFINITION OF PROTEIN SIGNATURES, AND A TEST FOR DETECTING D-AMINO ACID AND FOR SCREENING MOLECULES CAPABLE OF INHIBITING THE ACTIVITY OF RACEMASE, ESPECIALLY PROLINE RACEMASE - This invention relates to the identification and characterization of racemases and definition of protein signatures of these racemases. More particularly, this invention relates to the identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs and more specifically SEQ ID NOS:1-4. This invention also relates to antibodies specific for the peptides and to immune complexes of these antibodies with the peptides. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides. | 08-05-2010 |
| 20100183645 | ACTIVE OR PASSIVE IMMUNIZATION AGAINST PROAPOPTOTIC NEUROTROPHINS FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES - The present invention relates to novel methods for combating cell degeneration or dysfunction resulting from neuroinflammatory conditions. The invention especially relates to the use, in the preparation of a medicament for the treatment of neurodegenerative disease associated with neuroinflammation, of an immunogenic compound which is capable of inducing an immune response against a proapoptotic neurotrophin, or an effective amount of a hapten combined with appropriate carriers and/or adjuvants to render the resulting combination capable of inducing an immune response against a proapoptotic neurotrophin. Also disclosed are compositions for the active or passive immunization against neuronal or glial cell apoptosis caused by neuroinflammation as well as methods and means useful for said active or passive immunization. | 07-22-2010 |
| 20100167317 | PROCESS FOR ENRICHING BASOPHILS IN A BLOOD SAMPLE - The present invention is based on the discovery that contrary to prior studies CD16 is expressed by basophils and as such provide methods and kits for enriching basophils in a blood sample. | 07-01-2010 |
| 20100159480 | BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue. | 06-24-2010 |
| 20100158912 | MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE - Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample. | 06-24-2010 |
| 20100150951 | PLASMODIUM FALCIPARUM ANTIGENS INDUCING PROTECTIVE ANTIBODIES - The present invention provides a vaccine against malaria containing a polypeptide having an epitope contained within a merozoite surface protein and a method for immunizing against malaria by administering the vaccine. | 06-17-2010 |
| 20100145008 | OB-FOLD USED AS SCAFFOLD FOR ENGINEERING NEW SPECIFIC BINDERS - The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule. | 06-10-2010 |
| 20100144615 | NUCLEOTIDE SEQUENCE ENCODING A MODULATOR OF NF-KB - The present invention relates to nucleotide sequences encoding a modulator of NF-κB, and to the polypeptides encoded by the nucleotide sequences. In particular, the invention relates to nucleotide sequences and the polypeptides encoded thereby, wherein the polypeptides are involved in the response to NF-κB-activating stimuli, including HTLV-1 Tax, LPS, PMA and IL-1. The invention also relates to antibodies to the modulator of NF-κB, methods of detecting modulator of NF-κB using the antibodies, methods of treatment associated with NF-κB activation and to methods of identifying compounds which modulate the activity of the modulator of NF-κB. | 06-10-2010 |
| 20100138938 | METHOD OF PRODUCING A MULTICHIMERIC MOUSE AND APPLICATIONS TO STUDY THE IMMUNOPATHOGENESIS OF HUMAN TISSUE-SPECIFIC PATHOLOGIES - The invention relates to a method of producing a multichimeric mouse comprising a functional xenogenic (human) immune system restricted to the MHC class I and/or class II molecules (HLA molecules) of the xenogenic species solely, and a functional tissue. The invention relates also th the use of the multichimeric mouse obtainable by said method, to study the immunopathogenesis of tissue-specific diseases (infectious, tumoral or auto-immune pathologies) and to their applications to design and test vaccines or immunotherapeutic agents against these pathologies. | 06-03-2010 |
| 20100130371 | SYSTEM, METHOD, DEVICE, AND COMPUTER PROGRAM PRODUCT FOR EXTRACTION, GATHERING, MANIPULATION, AND ANALYSIS OF PEAK DATA FROM AN AUTOMATED SEQUENCER - A system, method, device, and computer program product to extract and gather peak information from an automated sequencer of bioinformatics into a peak database, and to manipulate and analyze the peak information within the database. | 05-27-2010 |
| 20100111924 | Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. | 05-06-2010 |
| 20100099854 | NEUROVIRULENT STRAIN OF THE WEST NILE VIRUS AND USES THEREOF - Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof. | 04-22-2010 |
| 20100093985 | USE OF AT LEAST ONE CYTOSOLIC PHOSPHOLIPASE A2 INHIBITOR AS A MEDICINE FOR SYMPTOMATIC TREATMENT OF MUCOVISCIDOSIS - A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis. | 04-15-2010 |
| 20100074533 | FEATURE ADAPTED BEAMLET TRANSFORM APPARATUS AND ASSOCIATED METHODOLOGY OF DETECTING CURVILINEAR OBJECTS OF AN IMAGE - A method of detecting a curvilinear object of a noisy image. The method includes filtering the noisy image in accordance with a two dimensional line profile. The line profile is selected within a class of steerable filters. A beamlet coefficient is calculated in accordance with the filtering, wherein a coefficient above a predetermined threshold identifies a local feature | 03-25-2010 |
| 20100062438 | NATURAL SELECTION AND CELLULAR IMMORTALITY - The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes. | 03-11-2010 |
| 20100055109 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS - The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving a chronic pain and/or neuron loss. | 03-04-2010 |
| 20100041072 | PROCESS FOR IDENTIFYING A LIGAND THAT BINDS TO THE NEP BINDING SITE FOR THE SMR1 PENTAPEPTIDE - The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human. | 02-18-2010 |
| 20100041036 | GENOMIC MORSE CODE - The present invention relates to a method of detection of the presence of at least one domain of interest on a macromolecule to test, wherein said method comprises the following steps: a) determining beforehand at least two target regions on the domain of interest, designing and obtaining corresponding labeled probes of each target region, named set of probe of the domain of interest, the position of these probes one compared to the others being chosen and forming the specific signature of said domain of interest on the macromolecule to test; b) after spreading of the macromolecule to test on which the probes obtained in step a) are bound, detection of the position one compared to the others of the probes bound on the linearized macromolecule, the detection of the signature of a domain of interest indicating the presence of said domain of interest on the macromolecule to test, and conversely the absence of detection of signature or part of signature of a domain of interest indicating the absence of said domain or part of said domain of interest on the macromolecule to test. | 02-18-2010 |
| 20100040577 | METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS - The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample. | 02-18-2010 |
| 20100028263 | Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus - compositions, especially those based on | 02-04-2010 |
| 20100021384 | USE OF VHH ANTIBODIES FOR THE PREPARATION OF PEPTIDE VECTORS FOR DELIVERING A SUBSTANCE OF INTEREST AND THEIR APPLICATIONS - Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell. | 01-28-2010 |
| 20100015685 | LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES - The invention concerns novel polypeptides and their fragments, isolated from | 01-21-2010 |
| 20100011450 | IMMUNODEFICIENT MICE TRANSGENIC FOR HLA CLASS I AND HLA CLASS II MOLECULES AND THEIR USES - The invention relates to mice which are genetically deprived of T, B lymphocytes and NK cells, deficient for murine MHC class I and/or MHC class II molecules, and transgenic for the expression of the HLA class I and/or HLA class II molecules, and to their use as recipient hosts for the transplantation of human haematopoietic precursors, to study the human adaptative immune system development and function in vivo. The invention relates also to the applications of this human/mouse chimera model to improve immunotherapy against pathogens, cancer and autoimmune diseases. | 01-14-2010 |
| 20100009909 | PEPTIDES BINDING THE PHOSPHATASE 2A PROTEIN - The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides encoding the novel peptides, vectors expressing same, as well as antibodies identifying same and probes identifying transcripts thereof. | 01-14-2010 |
| 20090318382 | USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION - A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain. | 12-24-2009 |
| 20090304637 | RECOMBINANT MYCOBACTERIUM STRAIN EXPRESSING A MYCOBACTERIAL FAP PROTEIN UNDER THE CONTROL OF A PROMOTER ACTIVE UNDER HYPOXIA AND ITS APPLICATION FOR CANCER THERAPY - The invention relates to a recombinant vector comprising a mycobacterial FAP protein coding sequence under the transcriptional control of a promoter active under hypoxia conditions and its use for the prevention and the treatment of epithelial tumors. | 12-10-2009 |
| 20090298109 | METHOD FOR IDENTIFYING BPLP AND OPIORPHIN AGONISTS OR ANTAGONISTS - A method for in vitro functional characterization of Opiorphin derivatives by using highly selective biochemical assays. The method may employ an assay involving contacting an Opiorphin derivative with an enkephalin-inactivating ectopeptidase, such as neutral endopeptidase NEP (EC 3.4.24.11) or aminopeptidase AP-N (EC 3.4.11.2). This method provides a rapid and sensitive assay for measuring activity of these two membrane-anchored ectoenzymes when contacted with Opiorphin derivative by means of a selective fluorescence-based enzyme model. | 12-03-2009 |
| 20090280146 | CONTROL OF INTESTINAL INFLAMMATORY SYNDROMES WITH A PREPARATION OF KILLED OR NON INFECTIOUS BACTERIA - This invention relates to the use of a preparation of killed or non infectious Gram positive bacteria such as Gram positive facultative intracellular bacteria, for example mycobacteria, for the treatment of intestinal inflammatory syndromes such as Crohn's disease or ulcerative colitis. | 11-12-2009 |
| 20090271125 | METHOD AND SYSTEMS FOR LOCATING A SOURCE OF PARTICLE, MOLECULE, OR FRAGMENT OF MOLECULE - A method and systems for locating a source of particles, molecules, or fragments of molecules using particle, molecule, or fragment of molecule reception rate is disclosed. According to the invention, the particle, molecule, or fragment of molecules diffusion parameters in the search space are determined and a lattice is designed on the search space. After having determined whether or not at least one particle, molecule, or fragment of molecule is detected by a sensor, a probability is computed for each node of said search space lattice. The probability associated to each node of the search space lattice corresponds to the probability that the particle, molecule, or fragment of molecule source is located on the node. Then, the move of the sensor is evaluated according to the entropy of the computed probabilities. | 10-29-2009 |
| 20090269748 | IDENTIFICATION OF SUBSTANCES THAT INHIBIT NEMO OLIGOMERIZATION - The present invention provides methods for screening for substances which inhibit the oligomerization of NEMO and/or IKK-related complexes and/or signaling pathways based on the interference with NEMO oligomerization | 10-29-2009 |
| 20090263368 | Genetic variations associated with psychiatric disorders - The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination of whether an individual is susceptible of being afflicted by a psychiatric disorder such as autism spectrum disorders (ASD), Deficits and Hyper Activity Disorder (ADHD) and anorexia. | 10-22-2009 |
| 20090258394 | METHOD FOR THE PRODUCTION OF HIGH-LEVEL SOLUBLE HUMAN RECOMBINANT INTERFERON ALPHA IN E. COLI AND VECTORS USEFUL FOR SUCH A PRODUCTION - A method for the production of high-level soluble human recombinant interferon alpha protein (rhuIFNα) in | 10-15-2009 |
| 20090253639 | OPIORPHIN PEPTIDE DERIVATIVES AS POTENT INHIBITORS OF ENKEPHALIN-DEGRADING ECTOPEPTIDASES - The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases. | 10-08-2009 |
| 20090226468 | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS - The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and -gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells. | 09-10-2009 |
| 20090214635 | IDENTIFICATION OF A CONSERVED REGION OF PLASMODIUM FALCIPARUM MSP3 TARGETED BY BIOLOGICALLY ACTIVE ANTIBODIES - Antigenic and immunogenic determinants of Merozoite surface protein 3 (MSP3). Antigenicity and functional assays identified a 68-amino acid conserved domain of MSP3 as a target of biologically active antibodies. A peptide comprising amino acid residues 184-251 of SEQ ID NO: 2, may also be employed as may peptides consisting of different combinations of the MSP3 a, b, c, d, e and f peptides. Particular non-overlapping or overlapping segments of MSP3 a, b, c, d, e and f peptides may also be used. The various overlapping segments and nonoverlapping segments among the different MSP3 peptides are shown in FIG. | 08-27-2009 |
| 20090202992 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 08-13-2009 |
| 20090175892 | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 07-09-2009 |
| 20090175541 | Feature adapted beamlet transform apparatus and associated methodology of detecting curvilinear objects of an image - A method of detecting a curvilinear object of a noisy image. The method includes filtering the noisy image in accordance with a two dimensional line profile. The line profile is selected within a class of steerable filters. A beamlet coefficient is calculated in accordance with the filtering, wherein a coefficient above a predetermined threshold identifies a local feature. | 07-09-2009 |
| 20090162847 | RAPID DETECTION OF THE "HIGH-VIRULENT" ST-17 CLONE OF GROUP B STREPTOCOCCUS - The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B | 06-25-2009 |
| 20090142371 | HIV RECOMBINANT VACCINE - Reagents and methods for making and using HIV recombinant vaccines are disclosed. | 06-04-2009 |
| 20090136565 | Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R - This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active fragment of TNR, or a TNR agonist in an amount sufficient to direct migration of the neuronal progenitor cells. The invention provides a method of treating neurological diseases by replenishing diseased, damaged, or destroyed neural cells in the central nervous system or in the peripheral nervous system. | 05-28-2009 |
| 20090117554 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a method and a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 05-07-2009 |
| 20090110700 | ACELLULAR IMMUNOGENIC COMPOSITIONS AND ACELLULAR VACCINE COMPOSITIONS AGAINST BACILLUS ANTHRACIS - The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against | 04-30-2009 |
| 20090098535 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 04-16-2009 |
| 20090093428 | Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis - Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers. | 04-09-2009 |
| 20090087832 | Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products - DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed. | 04-02-2009 |
| 20090081788 | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof - An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes. | 03-26-2009 |
| 20090081665 | METHOD OF DIAGNOSIS/PROGNOSIS OF HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA COMPRISING THE PROFILING OF LPL/ADAM GENES - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a subject a patient in need thereof. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 03-26-2009 |
| 20090061480 | NUCLEOTIDE SEQUENCE ENCODING A MODULATOR OF NF-KB - The present invention relates to nucleotide sequences encoding a modulator of NF-κB, and to the polypeptides encoded by the nucleotide sequences. In particular, the invention relates to nucleotide sequences and the polypeptides encoded thereby, wherein the polypeptides are involved in the response to NF-κB-activating stimuli, including HTLV-1 Tax, LPS, PMA and IL-1. The invention also relates to antibodies to the modulator of NF-κB, methods of detecting modulator of NF-κB using the antibodies, methods of treatment associated with NF-κB activation and to methods of identifying compounds which modulate the activity of the modulator of NF-κB. | 03-05-2009 |
| 20090053237 | USE OF PENICILLIN-BINDING PROTEINS OR POLYNUCLEOTIDES OR ANTIBODIES THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS - The present invention is drawn to a penicillin-binding protein expressed by | 02-26-2009 |
| 20090017454 | BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue. | 01-15-2009 |
| 20090017073 | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof - A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis. | 01-15-2009 |
| 20080299608 | METHOD FOR THE IN VIVO MODIFICATION OF THE SYNTHESIS ACTIVITY OF A METABOLITE BY MEANS OF THE MODIFICATION OF A GENE THE ACTIVITY OF WHICH IS NOT THE ORIGINAL ACTIVITY - The invention relates to a method for altering a protein X such as to modify the characteristics thereof by a) obtaining the mutants X* of the sequence coding for protein X, by means of aleatory mutagenesis, b) transformation of cells with a phenotype [P-] with vectors comprising the mutated nucleic acids obtained in step (a) which code for proteins X*, where P-signifies that said cells are auxotrophic for substance P, P begin the product of the action of X on the natural substrate thereof S, c) culturing said cells in a medium comprising a substrate S*, S* being an analogue of the natural substrate S of the protein X, d) selection of the cells [P-:: X*] which have survived step c) in which the proteins X* can biosynthesise the product P from the substrate S*. The invention further relates to mutated proteins X, nucleic acids, expression vectors, host cells comprising a vector, use of N-dideoxyribosyl transferases for the transfer of a dideoxyribose (ddR) from a dideoxyribonucleoside to another nucleoside, a method for production of compounds comprising a step using a mutated protein and a strain of | 12-04-2008 |
| 20080293620 | Immunogenic Glycopeptides for Diagnosing Pathogenic Microorganisms Infections - A method for diagnosing an infection in a patient likely to be infected with a pathogenic microorganism, comprising the detection of CD4+ T lymphocytes recognizing at least one glycopeptide derived from said pathogenic microorganism, essentially consisting of a glycosylated T epitope, comprising from 14 to 25 amino acids, among which at least one neutral amino acid is bonded to a disaccharide or to a trisaccharide, and at least 15% of said amino acids are prolines, one of the prolines being located in position −1 to −4, relative to the position of said neutral amino acid. | 11-27-2008 |
| 20080276328 | METHODS FOR IDENTIFYING ANTI-TUMOR AND/OR ANTI-ANGIOGENESIS DRUGS WITH DEOXYNUCLEOSIDE 5'-MONOPHOSPHATE N-GLYCOSIDASE AS THE TARGET - The present invention relates to a novel target for identifying and/or screening antitumor and/or antiangiogenesis agents using the rcl encoded deoxynucleoside 5′monophosphate N-glycosidase. | 11-06-2008 |
| 20080261241 | Targeted ubiquitination of proteins and screening methods using a new class of ubiquitin ligase proteins - Members of the IpaH superfamily constitute a novel class of E3 ubiquitin ligases which are useful for engineering products which modulate trafficking and destruction of target proteins inside a cell and useful targets for identifying new antimicrobial molecules which modulate, especially inhibit, E3 ligases. | 10-23-2008 |
| 20080261212 | Method of Diagnosis/Prognosis of Human Chronic Lymphocytic Leukemia Comprising the Profiling of Lpl/Adam Genes - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a patient in need thereof and methods to determine IgVH mutational status. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 10-23-2008 |
| 20080250513 | LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES - The invention concerns novel polypeptides and their fragments, isolated from | 10-09-2008 |
| 20080233599 | IMMUNOGENIC GLYCOPEPTIDES, SCREENING, PREPARATION AND USES - The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position −1 to −4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunisation with the native glycopeptide from which they are derived, but are not identified by the T CD+4 lymphocytes induced by immunisation with a non-glycosylated peptide of same sequence and capable of inducing a proliferation of said T CD+4 lymphocytes by which they are identified and the secretion of cytokines by said lymphocytes and b1) glycopeptides having a sequence of 15 to 39 amino acids including the sequence of the glycopeptide as defined in a1), excluding the glycopeptide of sequence SEQ ID NO:11. | 09-25-2008 |
| 20080213879 | Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level - A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer(CRET). | 09-04-2008 |
| 20080213795 | DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes - The invention discloses isolated DNA sequences encoded by polypeptides characterized by the presence in their structure of one or more sequences bearing all or part of the one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of | 09-04-2008 |
| 20080213285 | SECRETED CHLAMYDIA POLYPEPTIDES, POLYNUCLEOTIDES CODING THEREFOR, THERAPEUTIC AND DIAGNOSTIC USES THEREOF - The present invention relates to secreted | 09-04-2008 |
| 20080207517 | SELECTIVE INHIBITION OF NF-kappaB ACTIVIATION BY PEPTIDES DESIGNED TO DISRUPT NEMO OLIGOMERIZATION - The present invention relates to polypeptides that inhibit the NF-κB signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO. | 08-28-2008 |
| 20080206230 | Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides - The invention relates to a peptide that is a maturation product of the Basic Prolin-rich Lacrinal Protein (BPLP) or a peptide derivative of said maturation product, wherein the peptide or peptide derivative exhibits an inhibitory property against a metallo-ectopeptidase, especially NEP and/or APN. | 08-28-2008 |
| 20080199496 | Genes Associated with Leishmania Parasite Virulence - The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania | 08-21-2008 |
